中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
16期
21-22,23
,共3页
老年人%非小细胞肺癌%化疗
老年人%非小細胞肺癌%化療
노년인%비소세포폐암%화료
Elderly%Non-small cell Lung cancer(NSCLC)%Chemotherapy
目的探讨老年晚期非小细胞肺癌（NSCLC）的化疗方案选择。方法对我院2000年6月至2007年6月收治的有完整资料85例（年龄≥70岁）老年非小细胞肺癌患者分为单药化疗组、铂类为基础的联合化疗两组，对其临床资料、治疗效果及不良反应进行回顾性对照分析。结果单药化疗组21例，铂类为基础的联合化疗64例。单药化疗组心、肝、肾等基础疾病合并率（100%）明显高于联合化疗组（P＜0.05）。铂类联合化疗组RR（39.1%），明显高于单药化疗组（23.8%）。铂类联合化疗组中位生存期（MST）11.5个月、疾病进展时间（TTP）7.4个月、1年生存率（38.3%）、2年生存率（18.5%）均显著高于单药化疗组（P＜0.05）。Ⅲ～Ⅳ度副反应发生率明显高于单药化疗组（P＜0.05），两组均未出现化疗相关死亡。结论高龄并非化疗禁忌，一般情况良好的老年晚期NSCLC患者可考虑选择铂类为基础的联合方案化疗，一般情况较差者，可行单药化疗。
目的探討老年晚期非小細胞肺癌（NSCLC）的化療方案選擇。方法對我院2000年6月至2007年6月收治的有完整資料85例（年齡≥70歲）老年非小細胞肺癌患者分為單藥化療組、鉑類為基礎的聯閤化療兩組，對其臨床資料、治療效果及不良反應進行迴顧性對照分析。結果單藥化療組21例，鉑類為基礎的聯閤化療64例。單藥化療組心、肝、腎等基礎疾病閤併率（100%）明顯高于聯閤化療組（P＜0.05）。鉑類聯閤化療組RR（39.1%），明顯高于單藥化療組（23.8%）。鉑類聯閤化療組中位生存期（MST）11.5箇月、疾病進展時間（TTP）7.4箇月、1年生存率（38.3%）、2年生存率（18.5%）均顯著高于單藥化療組（P＜0.05）。Ⅲ～Ⅳ度副反應髮生率明顯高于單藥化療組（P＜0.05），兩組均未齣現化療相關死亡。結論高齡併非化療禁忌，一般情況良好的老年晚期NSCLC患者可攷慮選擇鉑類為基礎的聯閤方案化療，一般情況較差者，可行單藥化療。
목적탐토노년만기비소세포폐암（NSCLC）적화료방안선택。방법대아원2000년6월지2007년6월수치적유완정자료85례（년령≥70세）노년비소세포폐암환자분위단약화료조、박류위기출적연합화료량조，대기림상자료、치료효과급불량반응진행회고성대조분석。결과단약화료조21례，박류위기출적연합화료64례。단약화료조심、간、신등기출질병합병솔（100%）명현고우연합화료조（P＜0.05）。박류연합화료조RR（39.1%），명현고우단약화료조（23.8%）。박류연합화료조중위생존기（MST）11.5개월、질병진전시간（TTP）7.4개월、1년생존솔（38.3%）、2년생존솔（18.5%）균현저고우단약화료조（P＜0.05）。Ⅲ～Ⅳ도부반응발생솔명현고우단약화료조（P＜0.05），량조균미출현화료상관사망。결론고령병비화료금기，일반정황량호적노년만기NSCLC환자가고필선택박류위기출적연합방안화료，일반정황교차자，가행단약화료。
Objective To study the therapeutic regimen in treatment of elderly patients with non-small cell lung cancer in advanced stage. Methods 85 patients age≥70 with advanced NSCLC lung cancer from Janu 2000to Janu 2007 were divided into two groups in our study, named single agent chemotherapy group, combined chemotherapy based on platinum. The clinical characteristics and treatment efficacy and adverse reaction were reviewed and compared. Results There were 21 cases in the single agent chemotherapy group, 64 cases in the combined chemotherapy based on platinum group. The underlying severe diseases ratio(100%) of the single agent group was significantly higher than combined chemotherapy based on platinum group(P<0.05). The response rate(RR) of combined chemotherapy with platinum group (39.1%) had notably higher than the single agent chemotherapy group(23.8%). The midian survival time(MST) (11.5 months), to treatment progress time(TTP) (7.4 months), one year survival rate(38.3%) and 2 years survival rate(18.5 %) were prominently higher than the single agent chemotherapy group (P<0.05). The Ⅲ~Ⅳ degree side effects of combined chemotherapy with platinum group had evident difference with the single agent chemotherapy group (P<0.05). Conclusion The elderly advanced NSCLC patients with good performance status could receive combined chemotherapy based on platinum. While the patients with bad performance status could receive single agent chemotherapy.
